CBIO Dividend History & Description — Gyre Therapeutics Inc
Catalyst Biosciences, together with its subsidiary, is a biopharmaceutical company focused on development and commercialization of Hydronidone for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease) in the U.S. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the U.S. and generated pharmacokinetic, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. When considering the Gyre Therapeutics Inc stock dividend history, we have taken known splits into account, such that the CBIO dividend history is presented on a split-adjusted ("apples to apples") basis. Gyre Therapeutics Inc dividend history is presented both in graphical/chart form, and as a CBIO dividend history data table along the right-hand column.